GB201603655D0

GB201603655D0 - Modified natural killer cells and natural killer cell lines having increased cytotoxicity

Modified natural killer cells and natural killer cell lines having increased cytotoxicity

Info

Publication number: GB201603655D0
Authority: GB; United Kingdom
Prior art keywords: natural killer; cell lines; increased cytotoxicity; killer cells; modified
Prior art date: 2016-03-02
Legal status : Ceased

Application number

GBGB1603655.0A

Current Assignee

Onkimmune Ltd

Original Assignee

Onkimmune Ltd

Priority date

2016-03-02

Filing date

2016-03-02

Publication date

2016-04-13

2016-03-02 Application filed by Onkimmune Ltd filed Critical Onkimmune Ltd

2016-03-02 Priority to GBGB1603655.0A priority Critical patent/GB201603655D0/en

2016-04-13 Publication of GB201603655D0 publication Critical patent/GB201603655D0/en

2016-07-28 Priority to EP18187137.7A priority patent/EP3421590B1/en

2016-07-28 Priority to BR112018001660-8A priority patent/BR112018001660A2/en

2016-07-28 Priority to ES16750677T priority patent/ES2701338T3/en

2016-07-28 Priority to EP20213303.9A priority patent/EP3971284B1/en

2016-07-28 Priority to EP21152473.1A priority patent/EP3828266B1/en

2016-07-28 Priority to ES18194107T priority patent/ES2876938T3/en

2016-07-28 Priority to JP2018524548A priority patent/JP6974681B2/en

2016-07-28 Priority to MX2018001074A priority patent/MX2018001074A/en

2016-07-28 Priority to EP16750677.3A priority patent/EP3317401B1/en

2016-07-28 Priority to EP21152246.1A priority patent/EP3878951A1/en

2016-07-28 Priority to ES20213303T priority patent/ES2970269T3/en

2016-07-28 Priority to RU2018104871A priority patent/RU2772348C2/en

2016-07-28 Priority to ES18187137T priority patent/ES2890859T3/en

2016-07-28 Priority to CA2993796A priority patent/CA2993796C/en

2016-07-28 Priority to AU2016300128A priority patent/AU2016300128B2/en

2016-07-28 Priority to EP18194107.1A priority patent/EP3434762B1/en

2016-07-28 Priority to CN201680049392.8A priority patent/CN108026512B/en

2016-07-28 Priority to CN202211000656.4A priority patent/CN116064401A/en

2016-07-28 Priority to ES21152473T priority patent/ES2939084T3/en

2016-07-28 Priority to PCT/EP2016/068001 priority patent/WO2017017184A1/en

2016-07-28 Priority to CN202210987123.3A priority patent/CN116064400A/en

2016-07-28 Priority to DK18187137.7T priority patent/DK3421590T3/en

2016-07-28 Priority to KR1020187005673A priority patent/KR20180028530A/en

2016-07-28 Priority to DK18194107.1T priority patent/DK3434762T3/en

2016-07-28 Priority to CA3156128A priority patent/CA3156128A1/en

2016-07-28 Priority to DK16750677.3T priority patent/DK3317401T3/en

2017-01-12 Priority to US15/405,163 priority patent/US10034925B2/en

2018-01-24 Priority to MX2020010014A priority patent/MX2020010014A/en

2018-01-31 Priority to US15/885,301 priority patent/US10906951B2/en

2018-07-11 Priority to US16/032,626 priority patent/US10960064B2/en

2018-09-17 Priority to HK18111896.2A priority patent/HK1252582B/en

2020-11-30 Priority to US17/107,696 priority patent/US20210138051A1/en

2020-12-23 Priority to US17/133,187 priority patent/US20210230241A1/en

2021-07-06 Priority to JP2021112019A priority patent/JP2021178824A/en

2021-07-06 Priority to JP2021112020A priority patent/JP7359346B2/en

2022-05-18 Priority to AU2022203339A priority patent/AU2022203339A1/en

Status Ceased legal-status Critical Current

Links

GBGB1603655.0A 2015-07-29 2016-03-02 Modified natural killer cells and natural killer cell lines having increased cytotoxicity Ceased GB201603655D0 (en)